OPK Biotech develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. Using its patented and proprietary technology, it has developed and manufactured two products: Hemopure (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use, and Oxyglobin (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use. The company has been developing Hemopure for the treatment of patients with cardiovascular ischemia and supporting the U.S. Navy's government-funded development of the product for out-of-hospital treatment of trauma patients in hemorrhagic shock. Oxyglobin, its veterinary product for the treatment of anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission.
Partial Data by Infogroup (c) 2024. All rights reserved.
Partial Data by Foursquare.